Core Viewpoint - The article discusses the impact of tariff uncertainties on alternative investments, particularly in emerging markets, and suggests a potential shift in investor focus towards developed markets in Asia and the MENA region due to these uncertainties [1][6]. Group 1: Investment Trends - Emerging markets can be categorized into two groups based on annual returns: one group with approximately 3% returns (Latin America, Central and Eastern Europe, CIS countries, and broader emerging markets) and another group with superior performance (developed markets in Asia and the MENA region) [6]. - Recent transactions highlight the operational environment and future investment potential in developed markets in Asia and the MENA region, such as the privatization of Skechers by 3G, which reflects concerns over potential new tax burdens on Chinese products [6]. - The acquisition of IO by OpenAI and the launch of the Stargate UAE project in the UAE indicate a growing trend in the AI sector, positioning the UAE as a leader in emerging industries and attracting investor interest [6]. Group 2: Future Outlook - Despite some stabilization in public markets since the introduction of initial tariff policies, investors continue to face significant uncertainties this year, necessitating agility and flexibility [7]. - The trend of production shifting from China to developed markets in Asia is expected to reshape the private equity landscape in the coming years, creating new investment opportunities in other emerging markets [7]. - The MENA region is poised to gain a more competitive position in the global investment landscape as a preferred area for AI companies [7].

But first, let's go for Wall Street's reaction. Bring in the co-anchor of CNBC's Squawkbox and a New York Times columnist, Andrew Ross Sorcin. Andrew, talk a little bit about the reaction that you're hearing from from Wall Street. Well, look, I think that Wall Street just wants to get this behind them. The question is whether they ultimately will. Um, you know, the other thing that happened this morning. So, you're going to be seeing the the markets wobbling this morning. And the reason the markets are wobb ...

Italian fashion house Armani Group reported a 5 percent drop in sales last year after the luxury sector was hit by macro-economic uncertainty and slowing demand in China https://t.co/GSUT3QNlw3 ...

Key Takeaways CMG's digital sales made up 35.4% of Q1 revenues, driven by mobile orders and strong brand loyalty. Comparable sales fell 0.4% as macro uncertainty led to fewer transactions despite menu innovation. CMG is boosting summer marketing and hospitality efforts to counter soft in-store traffic trends.Chipotle Mexican Grill (CMG) continues to see impressive traction in its digital sales, which represented a healthy 35.4% of total revenues in first-quarter 2025. The brand's mobile and online platfor ...

officer at Wealth Management. Alan, good morning. Good to see you, Frank.>> Always a pleasure to be here with you. >> So we were just kind of showing what we like to call the wall of worry using some air quotes there. Is there one of those in particular that you see as the biggest worry specifically for the markets.>> I think the biggest worry right now is around uncertainty, which breeds volatility and complexity. And when you look across the landscape, whether it be the situation in Washington, which you ...

When you look at trade negotiations right now, could they actually change the outcome of the European economy. Well, I think that there's going to be a very relevant factor. And if you see, for instance, if you watch our our predictions, they are different alternatives, different different scenarios according to the different outcomes that we might have.I hope that, you know, the negotiations will be finalized. So at least this, you know, will deliver a little bit of predictability because now, you know, th ...

There's a lot going on on inflation, growth, expectations and everything like that. But do you think the ECB is done cutting rates now. Good morning.I believe that I think the current situation that maybe to put it like this, that we are at income borders, that doesn't mean that we shouldn't be too complacent, but we are at our target. And this is really good news. I think when you look back where we started and we hiked ten times, we lowered eight times, now we are close to our target and this is good news ...

Investment Rating - The report provides a "Buy" rating for Bayer and Novo Nordisk, a "Reduce" rating for Eli Lilly, and a "Hold" rating for Gilead Sciences [5][15][19][24]. Core Insights - Investors are currently focused on regulatory uncertainties and their impact on growth and profitability in the pharmaceutical sector, while companies are optimistic about new product launches and growth drivers [2][4]. - The regulatory landscape remains unclear, with numerous items under debate, which could lead to varied outcomes for companies depending on their ability to adapt [3]. - Companies are planning a significant number of product launches, but the associated costs and the ability to generate these drugs remain in question until regulatory visibility improves [4][8]. Company Messaging into Results Bayer - Bayer trades at a 12-month forward PE multiple of 6x, with a target price of EUR32.00, implying an upside of 14.3% [10]. - The company expects Q2 2025 revenue to be impacted by patent erosion but anticipates recovery in Crop Science and continued momentum in Pharma [11]. Eli Lilly - Eli Lilly trades at a 12-month forward PE multiple of 33x, with a target price of USD675, indicating a downside of -12.4% [15]. - The company is expected to see strong growth in its Diabetes & Obesity Care segment, with a projected revenue of USD10.366 billion for Q2 2025 [16]. Gilead Sciences - Gilead trades at a target price of USD93.00, with a downside of -12.4% [19]. - The company is expected to see gradual revenue growth driven by the uptake of Yeztugo and Trodelvy, with total revenue projected at USD7.295 billion for Q2 2025 [20]. Johnson & Johnson - Johnson & Johnson trades at a forward PE multiple of 14x, with a target price of USD184.00, suggesting an upside of 21.6% [22]. - The company anticipates stable revenue growth in its Pharmaceutical division, with total revenue expected to reach USD22.980 billion in Q2 2025 [23]. Novo Nordisk - Novo Nordisk trades at a forward PE multiple of 18x, with a target price of DKK680, indicating an upside of 50.9% [24]. - The company is expected to maintain strong growth, particularly in its diabetes and obesity treatment segments, with a five-year forecast revenue CAGR of 12.1% [24].

Let's bring in former Dallas Fed President Richard Fiser. Richard, also Jeffrey's senior adviser and a CNBC contributor. And it's it's good to have you here, Richard.Well, if Steve says something, it is true. I just want you to know that. All right.Well, I guess we're done here. Um, no. So, we are I do have I I I think it's it's really fascinating this moment that we're in.You know, a lot of of assumptions have to uh kind of be pulled into service to figure out what the proper stance is. Now, part of what C ...

Core Insights - PepsiCo is facing challenges in its Frito-Lay North America (FLNA) business due to subdued snack demand, raising concerns about the company's future growth momentum [1][2] - The company reported a modest 1% year-over-year organic revenue growth in the FLNA segment, leading to a downward revision of its 2025 earnings guidance [2][10] - PepsiCo is implementing a multi-pronged recovery strategy, including dual-size pricing tiers and a focus on transforming its snack portfolio to meet changing consumer preferences [2][3] Financial Performance - PepsiCo's shares have declined approximately 13.8% year-to-date, contrasting with the industry's growth of 5.9% [7] - The forward price-to-earnings ratio for PepsiCo is 16.25X, which is below the industry average of 18.32X [9] - The Zacks Consensus Estimate indicates a year-over-year decline of 3.6% in 2025 earnings, with a projected growth of 5.2% in 2026 [10] Competitive Landscape - Mondelez International (MDLZ) is emerging as a key competitor, leveraging a diversified portfolio and focusing on high-growth segments like permissible indulgence and well-being snacks [4][5] - Campbell's Snacks division is gaining market share in the U.S. snack category, particularly in premium and health-conscious segments, responding quickly to consumer demand shifts [6]